CPT code 0435U designates a Proprietary Laboratory Analyses (PLA) test — specifically the ChemoID® assay produced by ChemoID® Lab and Cordgenics LLC — that evaluates ex vivo chemosensitivity by exposing bulk tumor cells and cultured cancer stem cells from a fresh tumor biopsy to a minimum of 14 chemotherapy agents or combinations. The code matters nationally as molecular and functional tumor profiling increasingly informs personalized oncology care and influences laboratory billing, coverage, and utilization patterns. Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical intent and laboratory setting for the test, an overview of common payer coverage landscapes and policy considerations, and what benchmarks and documentation elements typically matter for billing and claims adjudication. The report also outlines clinical context for use—targeting treatment selection in oncology through functional drug-response data—and summarizes where data is available and where input is limited. Data not available in the input includes specific payer coverage policies, reimbursement rates, ICD-10 linkage, and provider taxonomies.